We have investigated the role of leukocyte-endothelial cell interactions in a rabbit model of hemorrhagic vasculitis. Microvascular injury was produced in the skin by intradermal injection of Salmonella typhosa endotoxin followed 20 h later by intravenous zymosan, which activates complement. Hemorrhagic necrosis develops in the "prepared" skin sites which is characterized by microthrombi, neutrophil aggregation, platelet and fibrin deposition, and massive extravasation of erythrocytes. Hemorrhage in these Shwartzman-like lesions was quantitated by "'Tc-labeled autologous erythrocytes. Inhibition of the hemorrhagic response was obtained with mAb reactive with ICAM-1 as well as mAb against the leukocyte CD18 when either was administered intravenously just before intravenous zymosan challenge. This observation suggests that an intravascular event occurring in response to complement activation is required for the development of hemorrhagic vasculitis. We hypothesize that agents which successfully prepare the skin for the Shwartzman response after their intradermal injection do so by promoting increased intercellular adhesion molecule 1 (ICAM-1) expression on the vascular endothelium. Activation of complement then induces CD11/CD18 expression on circulating leukocytes thus producing an intravascular CD11/ CD18-ICAM-1 (leukocyte-endothelium) adhesion event. Inhibition of intravascular leukocyte-leukocyte aggregation with mAb against CDMlb (Mac-i) showed partial inhibition of hemorrhage, while mAb against CDMla (LFA-1) showed no inhibitory activity. This type of cytokine-primed, neutrophil-dependent vascular damage may be a model of human vasculitic processes where microvascular damage is produced in the absence of immune-complex deposition. (J. Clin. Invest. 1992.89:259-272.)
Introduction
The development of an inflammatory response requires the adhesion of activated neutrophils to vascular endothelium. While the inflammatory response consists ofevents which tend to localize and rid the host of invading pathogens, it is not uncommon to find that the same inflammatory response is responsible for significant host tissue damage resulting in morbidity and mortality. The adherence of leukocytes to vascular endothelium represents one of the functional consequences of the expression of a family of leukocyte surface glycoproteins. These adhesion molecules, referred to as the CD1 8 family of integrins, are heterodimers consisting of distinct alpha subunits: CDl la, CDl lb, and CDl lc, which associate with a common beta (CDl 8) subunit. CDl la/CD 1 8 is also called LFA-l, CDllb/CD18 is called Mac-l, and CDllc/CD18 is also known as p150,95 (1) . Stimulation of leukocytes by chemotactic factors including C5a, fMLP, and leukotriene B4 results in rapid expression (< 1 min) ofthese preformed receptor molecules on the plasma membrane (2-4) as well as increased functional activity of previously expressed adhesion molecules (5, 6) .
Recent studies have implicated intercellular adhesion molecule-l (ICAM-1)1 as at least one ligand for the CD 18 family of leukocyte integrins (1, 7) . ICAM-l expression is normally present at low levels on several nonhematopoietic cell types, but can be upregulated by a variety of cytokines. Stimulation of endothelial cells by interleukin 1, tumor necrosis factor, interferon y, as well as bacterial endotoxins, greatly increases ICAM-l expression by these cells (8, 9) . The significance of CDl 8/ICAM-1 interaction in contributing to certain inflammatory responses in vivo is clear (1) .
Proper regulation of neutrophil adhesion is critical to host defense. Over the past several years, a group of pediatric patients has been described which is genetically deficient in the CD18 adhesion glycoproteins (10, 1 in each sample was converted to blood equivalents by dividing by the specific activity (99Tc cpm/known blood volume) of the blood from that animal. Shwartzman-like lesions were produced in several additional animals, not labeled with 9'Tc, and skin lesions were prepared for routine histological evaluation. Antibody treatment. The mouse monoclonal antibody R6.5 (IgG2a, anti-human ICAM-1) has been described previously (15) . R 15.7, also a mouse monoclonal (IgGl) was raised against the canine CD18 adhesion glycoprotein. Its specificity was demonstrated by its ability to inhibit homotypic aggregation of JY cells (16) , and by its binding to mouse X human hybrids (17) expressing mouse CDl 1/human CD18 but not to hybrids expressing human CDl 1/mouse CD18. R7.1 (mouse IgG 1, antiCD I I a) binds to rabbit leukocytes as ascertained by flow cytometry. LM2 (mouse IgGl, antiCDl lb) has been described previously (18) . Purified mouse IgG was used as control. All antibodies, as purified protein, were dissolved in sterile saline and injected i.v. at 2 mg/kg.
Immunohistochemical demonstration of ICAM-1. In one additional animal, preparative injections of LPS were made as usual. 20 h later, biopsies of PBS-and LPS-injected skin were fixed and stained following the protocol of Gu and McGrath (19) . Briefly, samples were fixed in 4% paraformaldehyde, embedded in paraffin, cut in 5-Mum sections, dewaxed, and incubated with either mAb R6.5 or control mouse IgG. Detection of bound antibody was performed using biotinylated goat anti-mouse, peroxidase conjugated streptavidin and AEC substrate (BioGenex Laboratories, San Ramon, CA). 
Results
18-20 h after the intradermal injection ofS. typhosa endotoxin into rabbit skin, an accumulation ofleukocytes (mostly neutrophils, some monocytes) was seen, with the strongest reaction occurring in the deep dermis just above the panniculus carnosus muscle (Fig. 1) . In general, the accumulation of leukocytes had ceased by 18 h since dermal vessels were mostly free of adherent leukocytes and no evidence of microthrombi was seen. When animals were then challenged by systemic activation of complement, only the prepared intradermal sites became grossly hemorrhagic over a 4-6-h period (Fig. 2) . Histologically, the response to challenge consisted of intravascular aggregation of leukocytes (Fig. 3) , fibrin deposition, and massive extravasation of RBC's which was superimposed on the leukocyte accumulation induced by the endotoxin preparation. Quantitation of hemorrhage with autologous 99mTc-RBC showed an endotoxin dose-dependent response (Fig. 4) . When 100 Al of zymosan-activated rabbit plasma was substituted for endotoxin as the preparative injection, the hemorrhagic response after challenge was not significantly different from that of PBS-injected sites (14±4, 21±5, and 53±6 pl blood/site for PBS-, zymosan-activated plasma-, and LPS-injected sites, respectively).
To evaluate the role of ICAM-1 and the leukocyte integrins in the development of these hemorrhagic lesions, animals were pretreated with appropriate mAb. Administration of either antiCD18 or antiICAM-1 before both i.d. preparative and i.v. systemic challenge injections produced strong inhibition ofthe hemorrhagic response (Fig. 5) . While that protocol showed that the hemorrhagic response was dependent on both CD1 8 and ICAM-1, it was not known whether these antibodies blocked a response to the preparative injection, or blocked some aspect of the response occurring after systemic complement activation. We therefore modified the protocol to administer mAb only before systemic challenge. Fig. 6 shows that strong (> 80%) inhibition of hemorrhage was obtained when either the CD18 or ICAM-1 molecule was occupied before complement activation. While mAb recognizing CD1 lb (Mac-i ) produced significant inhibition (62%), mAb against CDl la (LFA-1) was without effect. -1) . Fig. 8 a illustrates that a significant basal CD 18 expression increased by threefold. Fig. 8 b shows that little binding of anti-CD1 la occurred until after zymosan injection.
While intravascular adhesion ofleukocytes to endothelium consistently occurred after i.v. challenge, the endothelium of animals pretreated with mAb reactive with CD 18 was relatively free of adherent leukocytes (Fig. 9) . Pretreatment with antiCDl lb did not inhibit leukocyte-endothelial adhesion, but intravascular leukocyte-leukocyte aggregation was not seen (Fig. 11) (14, 20) that accumulation of 51Cr-leukocytes peaks 3-4 h after the preparative injections, and that there was a direct, quantitative relationship between accumulation of leukocytes after preparation and the ensuing hemorrhage following challenge. Shwartzmanlike lesions don't develop in neutropenic animals (21), injection of neutrophil-derived proteases produces vascular damage which, ultrastructurally, resembles Shwartzman lesions (22) , and inhibition of leukocyte proteases effectively inhibits this hemorrhagic response (23) . These observations imply a requirement for neutrophil accumulation in local areas after exposure to a suitable preparative agent.
Our data suggest a different neutrophil dependence than protease release from accumulated leukocytes. When leukocytes were allowed to accumulate in the skin after i.d. endotoxin, and then mAb directed against the CD 18 leukocyte adhesion glycoprotein was administered as a single injection just before i.v. challenge, hemorrhagic lesions were dramatically inhibited. This observation suggests that leukocytes accumulated in the interstitium are not responsible for the ensuing hemorrhage, but that the intravascular leukocyte aggregation (Fig. 3) is what leads to the hemorrhagic response. Products of complement activation, as well as leukotrienes and bacterial chemotactic peptides activate neutrophils and stimulate, within minutes, the expression of preformed CD 18 complex on the leukocyte plasma membrane. We have now demonstrated that this upregulation occurs after the challenge injection in these experiments. This suggests, therefore, that the activation of circulating leukocytes results in a CD I 8-dependent leukocyte-endothelial cell adhesion which is a necessary event for the development of Shwartzman-like lesions. Fig. 9 Endotoxin (Pglsite) few neutrophils are adherent to the endothelium, most of the endothelial surface is free of adherent cells, and leukocyte aggregates as in Fig. 3 (14, 24) , endotoxin (14, 24) , IL-1(3 (20, 24) , TNFa (24) have been used successfully as preparative agents for the Shwartzman response. Endotoxin and these cytokines have also been shown to induce ICAM-1 expression on cultured vascular endothelial cells (8, 9, 25) Figure 6 . Effect of antiadhesion mAb on Shwartzman-induced hemorrhage in rabbit skin. In animals whose skin had been primed with i.d. LPS injections, mAb reactive with various adhesion molecules were administered i.v. at 2 mg/kg as a single dose, just before i.v. zymosan challenge. 6 h after challenge, the hemorrhagic lesions were removed from the skin, and the blood content of each was determined. The graph illustrates the effect of mAb on the 100 ,ug LPS/site lesions. AntiCD 18 and antiICAM-I were both very effective at blocking the development of hemorrhage. AntiCD I I a was not inhibitory, whereas antiCD l I b inhibited hemorrhage by 62%. like inflammatory lesions is the upregulation of ICAM-l on endothelium, and that the accumulated leukocytes in the interstitium after the preparative injection are as much a consequence ofICAM-l upregulation as is the hemorrhage following challenge. While these data suggest that a CDl 8-ICAM-I dependent leukocyte-endothelial cell adhesion is necessary for this vasculitis to occur, intravascular leukocyte-leukocyte aggregation appears also to be required. Anderson et al. (18) demonstrated that human granulocytes aggregate in response to C5a in vitro, and that this aggregation was inhibited by 97% by the same antiCDl lb (Mac-l) antibody used in our studies. Antibody recognizing CDl la (LFA-1) was not inhibitory. If one contrasts the intravascular aggregation seen in the uninhibited Shwartzman response (Fig. 3) with vessels from an animal pretreated with antiCDl lb (Fig. 11) , it is clear that while CD1 8/ ICAM-l dependent leukocyte adhesion was not completely inhibited as evidenced by a single layer ofleukocytes adherent to the vessel surface, no leukocyte aggregation occurred, and hemorrhage was partially inhibited in these animals.
We have previously shown, by intravital microscopic ob- 30 ,ug LPS ( Fig. 1 c) , X300. nism of disseminated intravascular coagulation (32 
